Genetics account for roughly 40 to 70 percent of a person’s risk of developing a drug addiction, depending on the substance. That doesn’t mean addiction is inevitable for anyone with a family history, and it doesn’t mean people without that history are safe. But heredity is the single largest category of risk factors, influencing everything from how your brain responds to a drug the first time you try it to how quickly your body breaks it down.
How Much of Addiction Risk Is Genetic
Twin studies, which compare identical twins (who share all their DNA) with fraternal twins (who share about half), are the gold standard for separating genetic influence from environmental influence. Across all substance use disorders, genetic factors account for about 50 percent of the total risk. But that number shifts depending on the drug.
Cocaine addiction has the highest heritability of any commonly studied substance, with estimates ranging from 0.40 to 0.80 and a weighted average around 0.72. That means genetic differences explain roughly 72 percent of the variation in who develops cocaine addiction. Alcohol use disorder falls around 0.50 to 0.64. Opioid dependence sits near 50 percent. Cannabis use disorder ranges from 0.51 to 0.59, and nicotine dependence spans a wide range of 0.30 to 0.70. Hallucinogens have the lowest heritability at about 0.39.
These numbers describe populations, not individuals. A heritability of 0.50 doesn’t mean half your personal risk comes from your genes. It means that across a large group of people, about half the variation in who becomes addicted and who doesn’t can be traced to genetic differences rather than environment.
Genes That Affect Reward and Craving
No single “addiction gene” exists. Instead, hundreds of genetic variants each nudge risk up or down by a small amount. A few, though, have been studied extensively enough to illustrate how the process works.
One well-known variant sits on the gene for a dopamine receptor in the brain’s reward system. The Taq A1 variant of this receptor gene has been linked to drug addiction, severe alcoholism, pathological gambling, and other impulsive behaviors. Dopamine is the chemical your brain releases when something feels rewarding. People with certain receptor variants may experience less natural reward from everyday activities, which can make the intense dopamine surge from drugs feel comparatively more compelling.
For opioids specifically, a variant on the gene that builds your brain’s primary opioid receptor (called OPRM1) has been tied to addiction susceptibility. In one study of Jordanian males, carrying a specific version of this gene variant increased the odds of drug addiction by about 59 percent compared to people without it. That single change alters how strongly your brain responds to opioids, both the natural ones your body produces and the synthetic ones in prescription painkillers or heroin.
Genes That Change How Your Body Processes Drugs
Not all addiction-related genes act in the brain. Some affect how quickly your liver breaks down a substance, which shapes the entire experience of using it.
A clear example involves nicotine. Your liver produces an enzyme that deactivates nicotine and clears it from your bloodstream. People carry different versions of the gene for this enzyme, and those versions determine whether you’re a normal, intermediate, or slow metabolizer. Slow metabolizers break down nicotine at 50 percent or less of normal speed. Because nicotine lingers longer in their system, they tend to get hooked faster when they start smoking. But there’s a twist: once dependent, slow metabolizers smoke fewer cigarettes, escalate more slowly, and are roughly 2.3 times more likely to quit than normal metabolizers. Their genetics made them vulnerable to initial addiction but also made recovery more achievable.
An even more dramatic example involves alcohol. Many people of East Asian descent carry a variant of a gene involved in alcohol metabolism that produces a nonfunctional version of the enzyme responsible for clearing acetaldehyde, a toxic byproduct of alcohol. When people with two copies of this variant drink, acetaldehyde builds up rapidly, causing intense facial flushing, nausea, and a racing heart. The reaction is so unpleasant that people homozygous for this variant rarely drink at all, and populations with high rates of the variant consistently show lower levels of alcoholism and higher rates of abstinence. This is one of the strongest known genetic protections against any addiction.
The Scale of Genetic Discovery
Early addiction genetics focused on a handful of candidate genes. Modern genome-wide studies scan millions of genetic markers across hundreds of thousands of people to find patterns. A recent large-scale analysis of 2.2 million individuals identified 708 locations in the genome associated with substance use disorders and related behaviors. Of those, 187 had never been identified in previous studies, and 403 had no prior association with any substance use trait in the scientific literature.
One important finding from this work is that many of the genetic influences on addiction aren’t substance-specific. They operate through a broader trait called behavioral disinhibition, a general tendency toward impulsivity, risk-taking, and difficulty controlling urges. The study identified 631 genetic loci linked to this broader trait, compared to just 48 linked specifically to substance use. In other words, much of what’s inherited isn’t a vulnerability to one particular drug. It’s a temperamental tendency that raises risk across multiple substances and impulsive behaviors.
Epigenetics: When Environment Rewrites the Script
Heredity and environment aren’t truly separate forces. They interact through a process called epigenetics, where life experiences change how your genes are read without altering the DNA sequence itself. Think of it as the difference between the words in a book and which paragraphs get highlighted. The text stays the same, but which parts get expressed changes.
Emotional stress and social hardship can trigger epigenetic changes that alter reward-signaling pathways in the brain, essentially priming someone to respond more positively to drugs. These changes involve chemical tags that get attached to DNA or to the proteins that package it, turning genes up or down. Animal studies show that environmental conditions can fully counteract or amplify genetic predispositions to addiction vulnerability.
Drug use itself also causes epigenetic changes. Cocaine exposure alters chemical tagging on genes involved in the brain’s reward center, increasing expression of proteins that drive compulsive drug-seeking. Chronic alcohol exposure changes how genes for certain brain receptors are expressed in ways that persist even after drinking stops. Opioid use modifies the chemical tags on the gene for the opioid receptor itself, potentially reducing the brain’s natural ability to manage pain and mood. Perhaps most striking, some of these changes can be passed to offspring. In animal studies, morphine exposure in mothers before mating produced offspring with increased anxiety and altered sensitivity to opioids, even though the offspring were never exposed to the drug directly.
These epigenetic effects are potentially reversible, which distinguishes them from permanent DNA mutations. That reversibility is part of what makes addiction treatment possible even for people with significant genetic risk.
Why Genetic Testing Isn’t Used Clinically
Given everything researchers know about the genetics of addiction, you might wonder whether a simple DNA test could predict your risk. Right now, the answer is no. SAMHSA, the federal agency that oversees substance abuse treatment in the United States, explicitly recommends against routine genetic testing as a sole indicator of addiction risk.
The reasons are practical. There are no standardized clinical guidelines for interpreting genetic results in the context of addiction prevention. Each individual variant contributes only a tiny amount of risk, and the interactions among hundreds of variants, plus epigenetic factors and environment, are too complex for current tests to capture meaningfully. A test might tell you that you carry a variant associated with slightly higher risk, but it can’t tell you whether you’ll develop an addiction any more than a family history questionnaire can.
The concern isn’t just accuracy. Without proper safeguards, genetic risk labels could lead to stigma, discrimination, or a false sense of security in people who test “low risk” but face significant environmental pressures. If genetic testing is eventually integrated into clinical care, guidelines emphasize it should be one component of a comprehensive assessment, never a standalone tool.
What This Means in Practical Terms
If addiction runs in your family, your risk is real but not predetermined. The roughly 50 percent of risk that comes from genetics leaves another 50 percent shaped by environment, choices, social support, mental health, and access to substances. People with high genetic risk who never encounter drugs, or who encounter them in a context with strong protective factors, may never develop an addiction. People with low genetic risk who face chronic stress, trauma, or easy access to highly addictive substances can still become addicted.
Family history remains the most accessible proxy for genetic risk. If a parent or sibling has struggled with addiction to any substance, your own vulnerability to substance use disorders in general is elevated, not just for the specific drug they used. That shared genetic architecture across different substances is one of the most consistent findings in addiction research. Being aware of that family pattern doesn’t predict your future, but it does give you information worth factoring into decisions about substance use.